About evitria
evitria is a company based in Schlieren (Switzerland) founded in 2010 was acquired by Atlas Antibodies in July 2021. evitria offers products and services including Recombinant Antibodies, Afucosylated Antibodies, Bispecific Antibodies, Fc-silenced Antibodies, and Other Proteins. evitria operates in a competitive market with competitors including GSK, Avidity Biosciences, Sutro Biopharma, Antheia and Vividion Therapeutics, among others.
- Headquarter Schlieren, Switzerland
- SectorsHealthcare
- Email••••••••
- Website evitria.com
- Social LinkedIn
- Acquired by Atlas Antibodies (Jul 2021)
- Legal Name Evitria Ag
- InvestorsAtlas Antibodies
& 2 more
- Acquired by
Products & Services of evitria
evitria offers a comprehensive portfolio of products and services, including Recombinant Antibodies, Afucosylated Antibodies, Bispecific Antibodies, Fc-silenced Antibodies, and Other Proteins.
Service for expressing antibodies in CHO cells with fast turnaround.
Antibodies enhanced for increased ADCC activity in therapeutics.
Antibodies targeting multiple antigens for complex applications.
Antibodies designed to reduce effector functions effectively.
Service for producing various secreted proteins as needed.
Investors in evitria
evitria has secured backing from 3 investors, including venture fund investors. Prominent investors backing the company include Atlas Antibodies, SHS Capital and Afinum.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Healthcare-focused private equity investments are managed by SHS Capital. | 1993 | shs-capital.eu | Tübingen, Germany | |
Private equity investments are managed by Afinum for mid-sized companies. | 2000 | afinum.de | Munich, Germany | |
Antibodies and research reagents targeting human proteins are developed. | 2006 | atlasantibodies.com | Stockholm, Sweden |
Investor details for evitria
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of evitria
1 people are tracked at evitria (1 in leadership).
| Name | Role | Group |
|---|---|---|
Christian Eberle | CEO | Leadership |
Complete people profiles for evitria
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of evitria
3 dated milestones of evitria across 11 years, from founding to its latest funding, stage changes and deals.
- Founded evitria is founded.
- Exit Acquired by Afinum.
- Exit Acquired by Atlas Antibodies.
Competitors of evitria
evitria operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as GSK, Avidity Biosciences, Sutro Biopharma, Antheia and Vividion Therapeutics, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| gsk.com | 1715 | Brentford, United Kingdom | – | 90,913 | Developer of pharmaceuticals and vaccines for various therapeutic areas | |
| aviditybiosciences.com | 2012 | San Diego, United States | $142.54M | 253 | Antibody-siRNA complexes are developed for cancer treatment. | |
| sutrobio.com | 2003 | United States | $171.85M | 235 | Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis. | |
| antheia.bio | 2013 | Palo Alto, United States | $152.37M | 50 | Yeast cells are genetically engineered to produce medicinal products. | |
| vividion.com | 2016 | Oceanside, United States | $270.5M | 123 | Developing novel drugs based on a proteome-wide ligand and target discovery platform | |
| synthego.com | 2012 | Redwood, United States | $459.75M | – | CRISPR-engineered cell and gene therapies are developed for research applications. | |
| korrobio.com | 2018 | Cambridge, United States | $4M | 77 | RNA-editing technologies are provided for precision medicine applications. | |
| univercells.com | 2013 | Charleroi, Belgium | $150.64M | 87 | Biomanufacturing technologies are supplied for biopharma antibody and vaccine production. | |
| savarapharma.com | 2008 | Austin, United States | $67.82M | 37 | Therapeutics for rare respiratory diseases are developed by Savara Pharma. | |
| lifeminetx.com | 2016 | Cambridge, United States | $300.07M | 85 | Developer of novel drugs from fungi via genome mining and recombinant overexpression |
Detailed competitors of evitria
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of evitria
The website of evitria (evitria.com) receives about 36.6K visits a month.
- Monthly visits36.6K
▼ 2.1% vs previous month
Websites whose visitors overlap most with evitria. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
creativebiolabs.net | creativebiolabs.net | 100% | – | #1,184,982 | – |
| raybiotech.com | 98% | 71.1K | #537,358 | View details | |
baculovirus.com | baculovirus.com | 94% | – | – | – |
gensat.org | gensat.org | 94% | – | #3,376,242 | – |
coxpress.sourceforge.net | coxpress.sourceforge.net | 94% | – | – | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 19 similar websites and full traffic analytics for evitria
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 19 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Latest news on Evitria
Complete news archive for evitria
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to evitria
10 companies that operate in the same segment as evitria (Life Sciences Platforms & Tools), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Medidata is recognized as a leading provider of SaaS solutions for clinical research. | 1999 | New York, New York, United States | USD 41.5 M | – | – | |
AI-based solutions for health management are provided. | 2015 | Dallas, Texas, United States | USD 2.8 B | – | – | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.3 B | USD 301.49 M | 1,480 | |
Real-world health data is provided for research and decisions. | 2012 | Menlo Park, California, United States | USD 259.16 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Biological reagents and antibodies are developed for life science research. | 1998 | Cambridge, Cambridgeshire, United Kingdom | USD 78.8 M | – | – | |
Electron microscopy services and microanalysis instruments are provided. | 1956 | Waltham, Massachusetts, United States | – | USD 44.56 B | 125,000 | |
Novel therapeutics are discovered using an AI-enabled drug platform. | 2013 | New York, New York, United States | USD 456.66 M | USD 74.68 M | – | |
A platform for sharing and accessing academic research papers is provided. | 2008 | San Francisco, California, United States | USD 58.4 M | – | – | |
Developer of molecular diagnostic testing solutions | 1996 | Sunnyvale, California, United States | USD 19.1 M | USD 54.88 M | 208 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about evitria
evitria was founded in 2010.
evitria is headquartered in Schlieren, Switzerland. It is registered at Schlieren, Zurich, Switzerland.
Christian Eberle is the current CEO of evitria.
Founded in 2010, evitria operates as a contract research organization based in Schlieren, Switzerland. Focus is placed on transient protein expression using CHO cells, with services extended to recombinant antibodies, afucosylated antibodies, and other proteins. Operations support biotech and pharmaceutical sectors through these specialized expression capabilities, enabling research and development in antibody and protein therapeutics.
evitria's top competitors include Sutro Biopharma, Synthego and Avidity Biosciences.
evitria offers Recombinant Antibodies, Afucosylated Antibodies, Bispecific Antibodies, Fc-silenced Antibodies, and Other Proteins.
evitria has 3 investors. Key investors include Atlas Antibodies, SHS Capital, and Afinum.
evitria operates through Evitria Ag.
Yes. evitria was acquired by Atlas Antibodies in July 2021.